Updating results

112 results

Sort: Relevance | Date

Thyroid disease

Proposed [GID-QS10088] Expected publication date: TBC

Quality standard Proposed

Parenteral nutrition in neonates

Proposed [GID-QS10087] Expected publication date: TBC

Quality standard Proposed

Diverticular disease

Proposed [GID-QS10086] Expected publication date: TBC

Quality standard Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Primary and secondary brain cancers

Proposed [GID-QS10092] Expected publication date: TBC

Quality standard Proposed

Tinnitus

Proposed [GID-QS10091] Expected publication date: TBC

Quality standard Proposed

Housing: planning to improve health and wellbeing

Proposed [GID-QS10117] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Abdominal aortic aneurysm

Proposed [GID-QS10035] Expected publication date: TBC

Quality standard Proposed

Prevention and non-surgical treatment of pelvic floor failure/incompetence/prolapse

Proposed [GID-QS10129] Expected publication date: TBC

Quality standard Proposed

Pernicious Anaemia

Proposed [GID-QS10130] Expected publication date: TBC

Quality standard Proposed

Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Technology appraisal guidance Proposed

Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Technology appraisal guidance Proposed

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery (ID1105)

Proposed [GID-TA10348] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

Proposed [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

Proposed [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

Proposed [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

Proposed [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Abicipar pegol for treating wet age-related macular degeneration ID1533

Proposed [GID-TA10511] Expected publication date: TBC

Technology appraisal guidance Proposed

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Proposed [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance Proposed

Midostaurin for treating advanced systemic mastocytosis ID1573

Proposed [GID-TA10503] Expected publication date: TBC

Technology appraisal guidance Proposed

Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

Proposed [GID-TA10507] Expected publication date: TBC

Technology appraisal guidance Proposed

Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing migraine [ID1372]

Proposed [GID-TA10454] Expected publication date: TBC

Technology appraisal guidance Proposed

Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

Proposed [GID-TA10450] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Technology appraisal guidance Proposed